<DOC>
	<DOCNO>NCT01841684</DOCNO>
	<brief_summary>This study evaluate safety effect anacetrapib low-density lipoprotein-cholesterol ( LDL-C ) add ongoing lipid-lowering therapy . The primary hypothesis treatment anacetrapib 100 mg 12 week low LDL-C great extent treatment placebo .</brief_summary>
	<brief_title>Efficacy Tolerability Anacetrapib Added Ongoing Lipid-Lowering Therapy Adult Participants With Homozygous Familial Hypercholesterolemia ( HoFH ) ( MK-0859-042 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Diagnosed HoFH genotyping If female , reproductive potential Have stabilize statin monotherapy statin therapy coadministered lipid medication least 6 week Severe chronic heart failure define New York Heart Association ( NYHA ) Classes III IV Uncontrolled cardiac arrhythmia , myocardial infarction ( MI ) , percutaneous coronary intervention ( PCI ) , coronary arterial bypass graft ( CABG ) , unstable angina stroke within 3 month prior Visit 1 plan procedure schedule within first 12 week study Uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins Active chronic hepatobiliary gall bladder disease History ileal bypass , gastric bypass , significant condition associate malabsorption Human immunodeficiency virus ( HIV ) positive Donated blood product phlebotomy &gt; 300 mL within 8 week intend donate 250_mL blood product receive blood product within project duration study Taking medication potent inhibitor inducer cytochrome P450 3A4 ( CYP3A4 ) , include limited cyclosporine , systemic itraconazole ketoconazole , erythromycin , clarithromycin , telithromycin , nefazodone , protease inhibitor , carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , St John 's wort ) discontinue treatment &lt; 3 week prior . Consumption &gt; 1 liter grapefruit juice per day also prohibit . Currently participate participate study investigational compound device within 3 month Consume 2 alcoholic drink per day Receiving treatment systemic corticosteroid systemic anabolic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HoFH</keyword>
</DOC>